ClinicalTrials.gg

Program

bulevirtide

Also written as “Bulevirtide” and “Bulevirtide (BLV)”.

Its studies are mostly in Hepatitis D, Chronic, led by 2 companies.

Furthest: phase 3, since Feb 21, 20195 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences40 open or runningphase 3since Feb 21, 2019Feb 21, 2019none ahead
Mirum Pharmaceuticals11 open or runningphase 3since Mar 2, 2026Mar 2, 2026Aug 31, 2027phase 3 · NCT07454837

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 21, 2019First study: phase 3 study in Hepatitis D, ChronicNew to Gilead SciencesGilead Sciences · NCT03852719 · 150 enrolled · United States, Germany, Italy and more
  2. Feb 21, 2019Phase 2 study in Hepatitis D, ChronicGilead Sciences · NCT03852433 · 175 enrolled · France, Moldova, Republic of, Romania and more
  3. Feb 27, 2023Phase 1 study in Chronic Hepatitis D InfectionGilead Sciences · NCT05760300 · 41 enrolled · United States
  4. Mar 1, 2023Phase 1 study in Hepatic ImpairmentGilead Sciences · NCT05765344 · 74 enrolled · United States
  5. Mar 2, 2026Mirum Pharmaceuticals's first study: phase 3 study in Hepatitis D, ChronicNew to Mirum PharmaceuticalsMirum Pharmaceuticals · NCT07454837 · 120 planned · Austria, Czechia, France and more

Ahead

  1. Aug 31, 2027Primary completion: phase 3 study in Hepatitis D, ChronicMirum Pharmaceuticals · NCT07454837

TargetBeta

SLC10A1 →read by rule
“Bile acid transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC10A1

ProgramCompanyFurthest phaseStudies
hepalatideruleshanghai-hep-pharmaceutical-co-ltdphase 38

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07454837Hepatitis D, Chronic · Austria, Czechia, France and more3RecruitingMirum PharmaceuticalsAug 31, 2027120
NCT05765344Hepatic Impairment · United States1CompletedGilead SciencesJan 10, 202574
NCT05760300Chronic Hepatitis D Infection · United States1CompletedGilead SciencesJul 18, 202441
NCT03852719Hepatitis D, Chronic · United States, Germany, Italy and more3CompletedGilead SciencesNov 26, 2020150
NCT03852433Hepatitis D, Chronic · France, Moldova, Republic of, Romania and more2CompletedGilead SciencesApr 5, 2022175

How it is read

Names in the registry

  • “Bulevirtide”, 5 entries
  • “Bulevirtide (BLV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.